Neuberger Berman Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$269M Buy
1,234,836
+51,940
+4% +$11.5M 0.2% 97
2025
Q4
$270M Sell
1,182,896
-5,060
-0.4% -$1.15M 0.2% 102
2025
Q3
$275M Sell
1,187,956
-52,298
-4% -$10.6M 0.2% 99
2025
Q2
$230M Sell
1,240,254
-132,804
-10% -$24.7M 0.18% 129
2025
Q1
$288M Sell
1,373,058
-111,196
-7% -$21.6M 0.24% 92
2024
Q4
$264M Sell
1,484,254
-737,973
-33% -$136M 0.21% 113
2024
Q3
$439M Buy
2,222,227
+268,852
+14% +$50.2M 0.34% 57
2024
Q2
$335M Buy
1,953,375
+99,497
+5% +$16.5M 0.28% 84
2024
Q1
$338M Buy
1,853,878
+271,927
+17% +$46.9M 0.28% 78
2023
Q4
$245M Buy
1,581,951
+13,791
+0.9% +$2.01M 0.21% 122
2023
Q3
$234M Sell
1,568,160
-27,778
-2% -$4.08M 0.21% 123
2023
Q2
$215M Sell
1,595,938
-169,599
-10% -$24.9M 0.19% 137
2023
Q1
$281M Buy
1,765,537
+192,280
+12% +$29.4M 0.26% 103
2022
Q4
$254M Buy
1,573,257
+538,677
+52% +$82.6M 0.25% 107
2022
Q3
$139M Sell
1,034,580
-156,026
-13% -$22.4M 0.15% 200
2022
Q2
$183M Buy
1,190,606
+54,935
+5% +$8.39M 0.18% 159
2022
Q1
$184M Buy
1,135,671
+13,831
+1% +$2.01M 0.16% 190
2021
Q4
$146M Buy
1,121,840
+148,914
+15% +$17.6M 0.11% 253
2021
Q3
$101M Sell
972,926
-532,681
-35% -$60.9M 0.09% 303
2021
Q2
$166M Buy
1,505,607
+449,737
+43% +$50.7M 0.14% 219
2021
Q1
$114M Buy
1,055,870
+420,875
+66% +$45M 0.11% 270
2020
Q4
$67.8M Sell
634,995
-225,282
-26% -$21.6M 0.07% 342
2020
Q3
$75.2M Sell
860,277
-63,605
-7% -$5.99M 0.09% 289
2020
Q2
$90.6M Buy
923,882
+382,265
+71% +$33.7M 0.11% 251
2020
Q1
$41.3M Buy
541,617
+77,925
+17% +$6.64M 0.06% 360
2019
Q4
$41.1M Buy
463,692
+9,239
+2% +$767K 0.05% 438
2019
Q3
$34.4M Sell
454,453
-25,325
-5% -$1.74M 0.04% 457
2019
Q2
$34.9M Sell
479,778
-2,510
-0.5% -$197K 0.04% 468
2019
Q1
$38.9M Sell
482,288
-56,083
-10% -$4.59M 0.05% 440
2018
Q4
$49.6M Sell
538,371
-38,542
-7% -$3.39M 0.07% 360
2018
Q3
$54.6M Sell
576,913
-20,933
-4% -$1.99M 0.06% 388
2018
Q2
$55.5M Sell
597,846
-4,322
-0.7% -$422K 0.06% 390
2018
Q1
$57.1M Sell
602,168
-138,433
-19% -$15.2M 0.07% 378
2017
Q4
$71.7M Buy
740,601
+128,013
+21% +$12.1M 0.08% 333
2017
Q3
$54.4M Buy
612,588
+14,176
+2% +$1.08M 0.07% 378
2017
Q2
$43.4M Buy
598,412
+3,546
+0.6% +$238K 0.06% 415
2017
Q1
$38.8M Buy
594,866
+3,907
+0.7% +$246K 0.05% 437
2016
Q4
$37M Sell
590,959
-17,884
-3% -$1.09M 0.05% 438
2016
Q3
$38.4M Sell
608,843
-39,779
-6% -$2.58M 0.05% 438
2016
Q2
$40.2M Sell
648,622
-57,282
-8% -$3.49M 0.06% 416
2016
Q1
$40.3M Buy
705,904
+40,790
+6% +$2.27M 0.06% 418
2015
Q4
$39.4M Sell
665,114
-73,667
-10% -$4.24M 0.05% 433
2015
Q3
$40.2M Buy
738,781
+83,584
+13% +$5.44M 0.05% 432
2015
Q2
$44M Sell
655,197
-39,678
-6% -$2.59M 0.05% 459
2015
Q1
$40.7M Sell
694,875
-14,346
-2% -$867K 0.04% 478
2014
Q4
$46.4M Sell
709,221
-163,005
-19% -$10.3M 0.05% 438
2014
Q3
$50.4M Sell
872,226
-515,941
-37% -$28.6M 0.05% 426
2014
Q2
$78.3M Sell
1,388,167
-502,944
-27% -$26.4M 0.08% 347
2014
Q1
$97.2M Sell
1,891,111
-2,486,305
-57% -$126M 0.1% 302
2013
Q4
$231M Sell
4,377,416
-691,235
-14% -$34M 0.24% 116
2013
Q3
$227M Sell
5,068,651
-73,263
-1% -$3.25M 0.25% 112
2013
Q2
$213M Buy
+5,141,914
New +$225M 0.25% 111

Other funds holding ABBV

Neuberger Berman Group's ABBV Position: Q1 2026 in Review

Neuberger Berman Group increased its AbbVie (ABBV) stake by 4.4% in Q1 2026, buying an estimated $11.5M and bringing the position to 1,234,836 shares worth $269M. The position accounts for 0.2% of the portfolio, ranked #97.

Neuberger Berman Group first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $439M in Q3 2024. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Neuberger Berman Group held 1,234,836 shares of AbbVie worth $269M as of Q1 2026.
  • Neuberger Berman Group bought 51,940 AbbVie shares in Q1 2026, an estimated $11.5M.
  • AbbVie made up 0.2% of Neuberger Berman Group's portfolio in Q1 2026, its #97 holding.
  • Neuberger Berman Group first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Neuberger Berman Group's AbbVie position peaked at $439M in Q3 2024.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.